MLYS Stock Summary and Trading Ideas (Mineralys Therapeutics | NASDAQ:MLYS)

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

Mineralys Therapeutics trades on the NASDAQ stock market under the symbol MLYS.

As of January 3, 2025, MLYS stock price climbed to $12.75 with 156,236 million shares trading.

MLYS has a beta of 2.17, meaning it tends to be more sensitive to market movements. MLYS has a correlation of 0.18 to the broad based SPY ETF.

MLYS has a market cap of $634.02 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that MLYS belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.

MLYS has outperformed the market in the last year with a price return of +49.1% while the SPY ETF gained +27.8%. However, in the short term, MLYS had mixed performance relative to the market. It has underperformed in the last 3 months, returning -1.2% vs +4.6% return in SPY. But in the last 2 weeks, MLYS shares have fared better than the market returning +3.3% compared to SPY +0.1%.

MLYS support price is $11.73 and resistance is $12.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MLYS shares will trade within this expected range on the day.